Sarepta Therapeutics Inc (SRPT) 15.19 $SRPT
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 315.06 (-2.97), CBST: 71.35 (-0.99), MDCO: 25.16 (-0.70), SRPT: 15.19 (+0.07), ALXN: 190.49 (-1.71), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
AMKR: 6.11 (-0.22), MXWL: 10.85 (-0.24), PCMI: 9.75 (+0.24), SRPT: 15.19 (+0.07), REXX: 8.15 (+0.43), WIRE: 36.92 (-0.07), LMNX: 19.03 (+0.27), PDCE: 44.22 (+1.85)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.11 (-0.22), KSS: 54.44 (-0.22), MU: 32.28 (-0.33), PFE: 29.49 (+0.40), HAL: 54.42 (+1.16), AMGN: 158.88 (+1.69), NQ: 7.81 (-0.19), RGC: 21.64 (+0.36), MS: 34.39 (+0.03), MSG: 74.72 (+1.73), NVAX: 5.41 (-0.07), CQB: 14.39 (unch), SRPT: 15.19 (+0.07), RCPT: 98.30 (+2.54), TWTR: 42.08 (-1.70), PTIE: 1.99 (-0.08)
Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 1:22PM CDT
Sarepta Therapeutics (SRPT) shares plunged 32.5% on news that the company will not be submitting its NDA for eteplirsen.
BIIB: 315.06 (-2.97), RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07), AMAG: 33.26 (-0.75)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.20 (-0.18), MRK: 56.20 (+0.35), PFE: 29.49 (+0.40), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Sarepta Slumps: SRPT Plunges 32.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:49AM CDT
Sarepta has been witnessing a flat trend in its current earnings estimate and it share price has been falling for past few days
BIIB: 315.06 (-2.97), SRPT: 15.19 (+0.07), AMAG: 33.26 (-0.75), ARRY: 3.81 (-0.03)
Sarepta tumbles on drug delay
at Investor's Business Daily - Mon Oct 27, 5:55PM CDT
The Cambridge, Mass.-based biotech's shares plummeted 32.5% to 15.91 after it said that the FDA is requiring more extensive information about its muscular dystrophy treatment, eteplirsen, before it will approve the drug. The announcement comes after...
SRPT: 15.19 (+0.07)
Can U.S. Stocks Go Higher if Oil Prices Keep Going Lower?
at The Street - Mon Oct 27, 1:56PM CDT
The "Fast Money" trading panel discussed the impact of falling oil prices on the stock market.
FDX: 165.77 (-2.43), BX: 30.00 (-0.55), NKE: 91.95 (-0.50), XBI: 169.62 (-1.89), GRMN: 53.96 (-3.24), PCL: 40.03 (-0.13), UPS: 102.62 (-0.28), TCBI: 59.96 (+0.25), UA: 64.27 (-0.03), SPY: 198.11 (-0.30), QQQ: 99.81 (-0.37), MPC: 87.41 (-1.71), SRPT: 15.19 (+0.07), MRK: 56.20 (+0.35), DIA: 169.40 (-0.26), STI: 38.62 (+0.19), CFG: 23.48 (+0.20), TEVA: 54.49 (-0.31), FL: 55.67 (+0.21), AAPL: 107.34 (+0.60), XLE: 85.99 (+0.28)
Petrobras Plunges In The Wake Of Brazilian Election Results
at The Street - Mon Oct 27, 12:15PM CDT
Odyssey Marine Exploration Inc (NASDAQ:OMEX), Tasman Metals Ltd (NYSEMKT:TAS) and ANADIGICS, Inc. (NASDAQ:ANAD) got a strong start to the day, making notable gains early this Monday. In the red are¿...
PBR: 11.21 (-0.47), CJES: 18.97 (+0.97), OMEX: 1.26 (-0.03), ANAD: 0.68 (+0.03), SRPT: 15.19 (+0.07)
Why Sarepta Therapeutics Inc Stock Is Crashing Today
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 12:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of clinical-stage biotech Sarepta...
SRPT: 15.19 (+0.07)
Sarepta Shares Falls on Duchenne Drug Approval Filing Delay
at The Street - Mon Oct 27, 10:02AM CDT
FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.
RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07)
Sarepta tumbles on new delay for key drug
AP - Mon Oct 27, 9:54AM CDT
NEW YORK (AP) — Shares of Sarepta Therapeutics plunged Monday after the company said regulators want more data about its muscular dystrophy treatment eteplirsen before they will consider approving the drug.
SRPT: 15.19 (+0.07)
Why I Won't Buy Ebola Stocks
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 9:28AM CDT
Source: Science Photo Library The recent outbreak of the deadly Ebola virus in Western Africa is now the worst on record, and public health officials are desperately searching for new ways to combat this serious threat to global health. As a...
INO: 11.20 (-0.18), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02)
Sarepta Therapeutics Announces Regulatory Update on Eteplirsen
Business Wire - Mon Oct 27, 6:00AM CDT
--FDA states further discussion needed to determine what constitutes a "complete" NDA submission;
SRPT: 15.19 (+0.07)
Could Sarepta Therapeutics Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 24, 8:13AM CDT
Source: Flickr user Purple Slog. There really is no industry quite like biotechnology. Whereas most businesses are valued based on the products or services they provide, the majority of the biotech sector is valued based on the diversity and...
RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07), GSK: 45.08 (-0.02)
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta
at The Street - Fri Oct 24, 7:28AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 2.38 (unch), RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07), RMTI: 9.48 (-0.04)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 80.56 (-1.49), ALNY: 91.53 (-2.72), SRPT: 15.19 (+0.07), SHPG: 196.45 (-1.35), NPSP: 27.21 (-0.91)
Research and Markets: Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical
Business Wire - Tue Oct 21, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gbp6qj/global_potential) has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020" report to their offering.
SRPT: 15.19 (+0.07), TKMR: 16.87 (-1.46)
Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical
M2 - Tue Oct 21, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/84gs7d/global_potential) has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020" report to their offering. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD). Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease. Summary As an example, government of the United States, through the FDA, has granted Fast Track designation to the Tekmira's TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by provid ing funds and floating favorable policies. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Market Definition and Scope - Key Findings - Key market player positioning - Ebola Virus Key Facts - Amend for anti-Ebola disease drugs in United States - Guidance on Air Medical Transport for Patients with Ebola Virus Disease - Fast Track designation to Anti-E bola drugs research from the U.S. government - ZMMP Drug: An Orphan solution for E-bola viral disease - Ethical Dilemmas from therapeutics - Tekmira Pharma received boost to ebola R&D through FDA fundings - Clinical Trials - Market Dynamics Chapter 4 Forecast Scenario Analysis Of Ebola Vaccines, 2013-2020, ($Million) - Moderate growth scenario - Rapid growth scenario - Diminishing growth scenario Chapter 5 Global Pipeline And Market Potential Analysis Of E-Bola Therapeutic Vaccines Market By Geography, 2013 - 2020 Chapter 6 Company Profiles - Tekmira Pharmaceuticals - BioCryst Pharmaceutical Inc. - Serepata Therapeutics - NewLink Genetics Corp. - Mapp Biopharmaceutical For more information visit http://www.researchandmarkets.com/research/84..._potential
SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 315.06 (-2.97), CBST: 71.35 (-0.99), MDCO: 25.16 (-0.70), SRPT: 15.19 (+0.07), ALXN: 190.49 (-1.71), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
AMKR: 6.11 (-0.22), MXWL: 10.85 (-0.24), PCMI: 9.75 (+0.24), SRPT: 15.19 (+0.07), REXX: 8.15 (+0.43), WIRE: 36.92 (-0.07), LMNX: 19.03 (+0.27), PDCE: 44.22 (+1.85)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.11 (-0.22), KSS: 54.44 (-0.22), MU: 32.28 (-0.33), PFE: 29.49 (+0.40), HAL: 54.42 (+1.16), AMGN: 158.88 (+1.69), NQ: 7.81 (-0.19), RGC: 21.64 (+0.36), MS: 34.39 (+0.03), MSG: 74.72 (+1.73), NVAX: 5.41 (-0.07), CQB: 14.39 (unch), SRPT: 15.19 (+0.07), RCPT: 98.30 (+2.54), TWTR: 42.08 (-1.70), PTIE: 1.99 (-0.08)
Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 1:22PM CDT
Sarepta Therapeutics (SRPT) shares plunged 32.5% on news that the company will not be submitting its NDA for eteplirsen.
BIIB: 315.06 (-2.97), RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07), AMAG: 33.26 (-0.75)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.20 (-0.18), MRK: 56.20 (+0.35), PFE: 29.49 (+0.40), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
Sarepta Slumps: SRPT Plunges 32.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:49AM CDT
Sarepta has been witnessing a flat trend in its current earnings estimate and it share price has been falling for past few days
BIIB: 315.06 (-2.97), SRPT: 15.19 (+0.07), AMAG: 33.26 (-0.75), ARRY: 3.81 (-0.03)
Sarepta tumbles on drug delay
at Investor's Business Daily - Mon Oct 27, 5:55PM CDT
The Cambridge, Mass.-based biotech's shares plummeted 32.5% to 15.91 after it said that the FDA is requiring more extensive information about its muscular dystrophy treatment, eteplirsen, before it will approve the drug. The announcement comes after...
SRPT: 15.19 (+0.07)
Can U.S. Stocks Go Higher if Oil Prices Keep Going Lower?
at The Street - Mon Oct 27, 1:56PM CDT
The "Fast Money" trading panel discussed the impact of falling oil prices on the stock market.
FDX: 165.77 (-2.43), BX: 30.00 (-0.55), NKE: 91.95 (-0.50), XBI: 169.62 (-1.89), GRMN: 53.96 (-3.24), PCL: 40.03 (-0.13), UPS: 102.62 (-0.28), TCBI: 59.96 (+0.25), UA: 64.27 (-0.03), SPY: 198.11 (-0.30), QQQ: 99.81 (-0.37), MPC: 87.41 (-1.71), SRPT: 15.19 (+0.07), MRK: 56.20 (+0.35), DIA: 169.40 (-0.26), STI: 38.62 (+0.19), CFG: 23.48 (+0.20), TEVA: 54.49 (-0.31), FL: 55.67 (+0.21), AAPL: 107.34 (+0.60), XLE: 85.99 (+0.28)
Petrobras Plunges In The Wake Of Brazilian Election Results
at The Street - Mon Oct 27, 12:15PM CDT
Odyssey Marine Exploration Inc (NASDAQ:OMEX), Tasman Metals Ltd (NYSEMKT:TAS) and ANADIGICS, Inc. (NASDAQ:ANAD) got a strong start to the day, making notable gains early this Monday. In the red are¿...
PBR: 11.21 (-0.47), CJES: 18.97 (+0.97), OMEX: 1.26 (-0.03), ANAD: 0.68 (+0.03), SRPT: 15.19 (+0.07)
Why Sarepta Therapeutics Inc Stock Is Crashing Today
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 12:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of clinical-stage biotech Sarepta...
SRPT: 15.19 (+0.07)
Sarepta Shares Falls on Duchenne Drug Approval Filing Delay
at The Street - Mon Oct 27, 10:02AM CDT
FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.
RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07)
Sarepta tumbles on new delay for key drug
AP - Mon Oct 27, 9:54AM CDT
NEW YORK (AP) — Shares of Sarepta Therapeutics plunged Monday after the company said regulators want more data about its muscular dystrophy treatment eteplirsen before they will consider approving the drug.
SRPT: 15.19 (+0.07)
Why I Won't Buy Ebola Stocks
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 9:28AM CDT
Source: Science Photo Library The recent outbreak of the deadly Ebola virus in Western Africa is now the worst on record, and public health officials are desperately searching for new ways to combat this serious threat to global health. As a...
INO: 11.20 (-0.18), SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02)
Sarepta Therapeutics Announces Regulatory Update on Eteplirsen
Business Wire - Mon Oct 27, 6:00AM CDT
--FDA states further discussion needed to determine what constitutes a "complete" NDA submission;
SRPT: 15.19 (+0.07)
Could Sarepta Therapeutics Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 24, 8:13AM CDT
Source: Flickr user Purple Slog. There really is no industry quite like biotechnology. Whereas most businesses are valued based on the products or services they provide, the majority of the biotech sector is valued based on the diversity and...
RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07), GSK: 45.08 (-0.02)
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta
at The Street - Fri Oct 24, 7:28AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 2.38 (unch), RNA: 11.09 (-1.09), SRPT: 15.19 (+0.07), RMTI: 9.48 (-0.04)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 80.56 (-1.49), ALNY: 91.53 (-2.72), SRPT: 15.19 (+0.07), SHPG: 196.45 (-1.35), NPSP: 27.21 (-0.91)
Research and Markets: Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical
Business Wire - Tue Oct 21, 3:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gbp6qj/global_potential) has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020" report to their offering.
SRPT: 15.19 (+0.07), TKMR: 16.87 (-1.46)
Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical
M2 - Tue Oct 21, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/84gs7d/global_potential) has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020" report to their offering. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD). Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease. Summary As an example, government of the United States, through the FDA, has granted Fast Track designation to the Tekmira's TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by provid ing funds and floating favorable policies. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Market Definition and Scope - Key Findings - Key market player positioning - Ebola Virus Key Facts - Amend for anti-Ebola disease drugs in United States - Guidance on Air Medical Transport for Patients with Ebola Virus Disease - Fast Track designation to Anti-E bola drugs research from the U.S. government - ZMMP Drug: An Orphan solution for E-bola viral disease - Ethical Dilemmas from therapeutics - Tekmira Pharma received boost to ebola R&D through FDA fundings - Clinical Trials - Market Dynamics Chapter 4 Forecast Scenario Analysis Of Ebola Vaccines, 2013-2020, ($Million) - Moderate growth scenario - Rapid growth scenario - Diminishing growth scenario Chapter 5 Global Pipeline And Market Potential Analysis Of E-Bola Therapeutic Vaccines Market By Geography, 2013 - 2020 Chapter 6 Company Profiles - Tekmira Pharmaceuticals - BioCryst Pharmaceutical Inc. - Serepata Therapeutics - NewLink Genetics Corp. - Mapp Biopharmaceutical For more information visit http://www.researchandmarkets.com/research/84..._potential
SRPT: 15.19 (+0.07), NLNK: 34.51 (-0.39), TKMR: 16.87 (-1.46)
